Breadth divergence is a troubling sign for the stock market

Celcuity stock soars after hours on breakthrough therapy designation for cancer drug

Posted on

Shares of Celcuity Inc. CELC were up 17% at $10.80 after hours as the U.S. Food and Drug Administration granted Breakthrough Therapy designation for a cancer drug.

The designation is for gedatolisib for certain patients with HR+/HER2- metastatic breast cancer.

Gedatolisib received Fast Track designation from the FDA in January.


Leave a Reply

Your email address will not be published. Required fields are marked *